EyePoint Pharmaceuticals, Inc.
EYPT
$14.52
$0.836.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -98.66% | -102.00% | -86.00% | -84.86% | -3.42% |
| Total Depreciation and Amortization | 75.36% | 114.13% | 161.93% | 231.90% | 72.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -16.23% | -9.46% | 9.71% | 131.74% | -22.30% |
| Change in Net Operating Assets | 21.52% | -36.94% | -164.82% | -147.17% | -151.24% |
| Cash from Operations | -85.85% | -112.56% | -1,089.11% | -6,832.05% | -1,015.51% |
| Capital Expenditure | 41.16% | 26.46% | 25.26% | -16.34% | -42.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 130.10% | 106.28% | -1,798.69% | -128,256.55% | -307.66% |
| Cash from Investing | 127.73% | 104.30% | -1,274.69% | -6,517.04% | -322.20% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -50.68% | -- | 99.60% | 99.77% | 99.87% |
| Issuance of Common Stock | -31.91% | -29.64% | -29.30% | -26.24% | 2,037.35% |
| Repurchase of Common Stock | 69.64% | 70.34% | 68.46% | -2,569.82% | -2,237.82% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -91.25% | 13.46% | 53.76% | 62.69% | 80.57% |
| Cash from Financing | -31.39% | -28.97% | -15.26% | -12.32% | 833.40% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 90.13% | 59.81% | -212.47% | -197.81% | -192.25% |